Somatic activating mutations of EGFR are associated with dramatic tumor-related therapeutic responses and favorable clinical outcomes for EGFR-TKIs in patients with NSCLC (Mitsudomi et al., 2010, Maemondo et al., 2010). The gene discussed is EGFR; the disease is neoplasm.